Talquetamab-tgvs
Talquetamab-tgvs is a Bispecific T-cell Engager (BiTE) immunotherapy targeting CD3 on the T cell and the G protein–coupled receptor class C group 5 member D (GPRC5D), which is highly expressed on the cell surface of multiple myeloma cells.
The drug is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received multiple lines of therapy.